PDCD1 and Miyoshi myopathy: Nowadays, there are several immunotherapy options for MM, such as anti-PD-1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody therapy, which represent desirable efficacy (3, 4).